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Direct Vascular Effects of Furosemide 
in Humans
Peter Pickkers, MD; Tom P J. Dormans, MD; Frans G.M. Russel, PhD; Alun D. Hughes, MD, PhD;
Theo Thien, MD, PhD; Nicolaas Schaper, MD, PhD; Paul Smits, MD, PhD
Background In humans, hemodynamic changes observed 
within minutes after systemic administration of furosemide are 
often referred to as direct vasoactivity. However, these imme­
diate changes do not per se imply a direct vascular effect. We 
examined the genuine direct vascular effects of furosemide on 
the human forearm vascular bed and dorsal hand vein.
Methods and Results Forearm blood flow in response to 
infusion of increasing dosages of furosemide into the brachial 
arte 17 was recorded by venous occlusion plethysmography. 
Local plasma concentrations of furosemide reached a maxi­
m um  of 234±40 ju,g/mL during the highest infused dose but did 
not significantly affect the ratio of flow in the infused/non in­
fused arms. Venous distensibility of a dorsal hand vein was 
measured with a linear variable differential transformer. D ur­
ing precontraction with norepinephrine, five increasing dosages 
of furosemide (1 to 100 /¿g/min) were administered locally. 
Additional experiments using local administration of indo- 
methacin or A/G-monomethyl-L-arginine (L-NMMA) were car­
ried out to determine whether effects were dependent on local
prostaglandin or nitric oxide synthesis, respectively. Also, the 
effects of systemic administration of furosemide were exam­
ined. Local administration of furosemide led to a dose-depen­
dent venorelaxati on of 18 ± 6% at the first to 72±16% at the 
last dose. Indomethacin almost completely abolished furo- 
semide-induced venorelaxation, whereas L-NMMA had no 
effect. Systemic administration of furosemide resulted in a 
time-dependent increase of hand vein distensibility, reaching 
45±11% after 8 minutes.
Conclusions Furosemide does not exert any direct arte­
rial vasoactivity in the human forearm , even at suprathera- 
peutic concentrations. In contrast, at concentrations esti­
mated to be in the therapeutic range, we observed a 
dose-dependent direct venodilator effect on the dorsal hand 
vein that appears to be mediated by local vascular prosta­
glandin synthesis. (Circulation. 1997;96:1847-1852.)
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T he loop-active diuretic furosemide has been the standard treatment for heart failure for several decades. Apart from its primary diuretic action, furosemide is also thought to have effects on the cardio­
vascular system. In heart failure, systemic administration 
of a loop-active diuretic has been reported to relieve the 
symptoms of pulmonary edema immediately, even be­
fore diuresis sets in.!>2 Although these effects are re­
ferred to as “direct” vascular effects, systemic adminis­
tration of a drug does not permit distinction between a 
direct action on the vascular wall versus changes induced 
by cardiovascular reflexes or regulatory systems.
It is well established that furosemide itself stimulates 
the release of renin, thereby increasing levels of angio­
tensin IP ’5 as well as of prostaglandins from the kidney.6 
T h e effects on these two vasoactive hormonal systems 
have been associated with arterial vasoconstriction and 
venous vasodilation observed after systemic administra-
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tion of the drug.3*4 Conversely, various in vitro experi­
ments indicate that furosemide, sometimes at rather 
high concentrations, does exert a direct vasodilator 
effect on isolated arterial7’8 and venous vessels.0 In the in 
vivo situation, this furosemide-induced direct arterial 
vasodilation could be blunted by the vasoconstrictive 
effects of angiotensin II after systemic administration, 
and it is not clear whether the previously reported in vivo 
venodilation1’3’10 is the resuit of a direct or indirect effect 
of furosemide on venous smooth muscle cells. Thus, up 
to now it is unknown whether furosemide-induced ef­
fects on systemic hemodynamics are the result of a direct 
or indirect action of the drug on the vasculature in vivo.
In the present study, we thoroughly investigated the 
genuine direct vascular effects of furosemide on resis­
tance arteries in the forearm and on the dorsal hand vein 
of healthy subjects. To this end, w e used the perfused 
forearm technique and the LVDT technique, respec­
tively. With these methods, interpretation of the results 
will not be confounded by direct effects on kidney or 




Several protocols using two techniques were conducted for 
this study, all approved by the local ethics committee. Before 
participation, written informed consent was obtained from a 
total of 60 healthy volunteers. Participants were asked to 
refrain from drinking alcohol or caffeine-containing beverages 
for at least 24 hours before their studies. Salt intake was not






Selected Abbreviations and Acronyms
= forearm arterial blood flow 
= A/G-monomethyl-L-arginine 
= linear variable differential transformer 
= nitric oxide 
= prostaglandin
restricted. None of the participants smoked or used any 
medication (including analgesics). All experiments were per­
formed in a single-blind fashion in a temperature-controlled 
laboratory (23°C to 24°C for the perfused forearm experiments 
and 28°C to 29°C for the venous distensibil ity measurements) 
with the subject in the supine position.
Demographic characteristics of the participants are summa­
rized in the Table.
Arterial Vascular Activity Measurements
Two protocols were conducted in a total of 22 subjects to 
assess the direct arterial vasoactivity of loop-active diuretics. 
First, we examined the direct arterial vasoactivity of furosemide 
and bumetanide and second, the effect of locally administered 
furosemide on norepinephrine-induced vasoconstriction. The 
perfused forearm technique was used for both protocols. For 
this technique, the left brachial artery was cannulated with a 
2Q-gauge catheter (Angiocath, Deseret Medical, Becton Dick­
inson) after induction of local anesthesia (lidocaine 2%). This 
catheter was used for drug infusion (automatic syringe infusion 
pump, type STC-521, Terumo) and blood pressure monitoring 
(Hewlett Packard GmbH). At least 30 minutes after intra-ar- 
terial cannulation, baseline values of FBF were measured in 
both arms three times per minute by ECG-triggered venous 
occlusion plethysmography with mercury-in-Silastic strain 
gauges (Hokanson EC4, DE Hokanson) .11 To ensure that FBF 
recordings referred predominantly to the forearm skeletal 
muscle resistance arteries, the hand circulation was occluded 
during all FBF recordings by a wrist cuff inflated 100 mm Hg 
above the systolic pressure . 12 The upper arm collecting cuffs 
were simultaneously inflated to 45 to 50 mm Hg with a rapid 
cuff inflator (Plokanson E-20). In all experiments, we also 
inserted a catheter into a deep ipsilateral forearm vein, During 
the last minute of each drug infusion period of 10 minutes, a 
venous blood sample was taken and drug concentrations were 
measured by high-performance liquid chromatography assay as 
previously described. 13
Direct Arterial Vasoactivity of Loop-Active Diuretics
Dosages of furosemide were normalized to forearm volume 
(water displacement method). Total infusion rate was kept 
constant at 100 ¡jlL • min ' 1 • 100 niL forearm volume“1. Furo­
semide was infused at 1, 3,10, 30, and 100 ¿xg • mill-1 * dL" 1 in 
8 subjects. In another 6 subjects, furosemide was infused at 
1000 ¡xg • min-1 ■ dL“1 for 6 minutes. In 4 subjects, we admin­
istered bumetanide (0.025, 0.075, 0.25, 0.75, and 2.5 jug • 
min-1 • dL"1) instead of furosemide to perceive possible differ­
ences in vasoactivity between these two loop-active diuretics.
Demographic Characteristics of the Study Groups




n (M/F) 22 (21/1) 38 (33/5)
Age, y 25.9±1.2 47.0+19.1
Weight, kg 77.3±1.4 75.0±6.8
Height, cm 183±2 182±6
Body mass index, kg/m2 23.0±0.4 22.7+2.0
Systolic blood pressure, mm Hg 128±3 134±22
Diastolic blood pressure, mm Hg 73±1 8Q±9
Data are mean±SD,
Effect of Furosemide on 
Norepinephrine-Induced Vasoconstriction
Animal data suggest that furosemide may exert an antivaso­
constrictor effect, because the drug did not directly dilate 
mesenteric resistance vessels but rather inhibited the vasocon­
strictor effect of norepinephrine and angiotensin II.14 To study 
this possible mechanism in humans, we measured the reduction 
of FBF in response to cumulative intra-arterial norepinephrine 
infusions in the absence and presence of local furosemide 
administration. In 4 subjects, norepinephrine was infused at 10, 
30, and 100 ng • min ' 1 • dL"1 before and after local adminis­
tration of furosemide (10 /xg * min“1 • dL-1 for 20 minutes, 
preceded by a 30-minute interval after the first norepinephrine 
dose-response curve). Previous experiments revealed that in- 
trabrachial infusion of this dose of furosemide led to clinically 
relevant concentrations in the infused forearm.
Venous Vascular Activity Measurements
Four protocols were carried out to determine the venous 
vasoactivity of furosemide. The direct venous effect of locally 
administered furosemide was examined, after which involve­
ment of vascular prostaglandin and NO synthesis was assessed. 
Also, the venous effect of systemic administration of furo­
semide was examined. All protocols were conducted by the 
LVDT technique, in which venous distensibility of a dorsal 
hand vein was measured with the LVDT as described by 
Aellig15 and evaluated by Alradi and Carruthers,lfi A total of 5.1 
experiments were performed in 28 young and 10 elderly 
subjects. Regression analysis established that there was no 
significant correlation between age and percentage venodila­
tion (/'=.18, P = NS), after which all data were pooled.
With the subject in the supine position in a temperature- 
controlled laboratory (28°C to 29°C), the arm under investiga­
tion was placed on a rigid support at an angle of 30° from the 
horizontal to allow complete emptying of the superficial hand 
veins. A sphygmomanometer cuff placed on the upper arm was 
then inflated to 45 mm Hg. A suitable large superficial vein 
with no apparent tributaries in the immediate area of exami­
nation was chosen, and a 23-gauge butterfly needle was in­
serted into the vein. The lightweight (0.2-g) probe of the LVDT 
was placed over the summit of the chosen vein 10 mm 
downstream from the tip of the needle. Under these condi­
tions, dorsal hand vein distensibility is maximal during venous 
occlusion. When the venous pressure remains constant at 
45 mm Hg, changes in venous diameter are proportional to 
changes in venous Lone.
Owing to the low venous tone present under these condi­
tions,17 venodilator effects can be quantified only on veins that 
have been preconstricted. To examine furosemide-induced 
venodilation, we used continuous infusion of increasing con­
centrations of norepinephrine to precontract the veins. Infu­
sion of the norepinephrine concentration that achieved a 
precontraction of «=30% of maximal vein diameter was sus­
tained throughout the experiment. Previous experiments from 
our laboratory showed that this method has a good reproduc­
ibility: In 15 subjects, the coefficient of variation of the maximal 
vasoconstrictor response to norepinephrine (before and after 
an interval of 2 hours) was 9%. In addition, norepinephrine 
dose-response curves on different days did not differ signifi­
cantly from each other. Sustained infusion of norepinephrine 
alone resulted in a stable vasoconstrictor response (70±7% 
contraction after 10 minutes and 73 ± 6% after 60 minutes, 
n = 10), indicating the absence of tachyphylaxis to norepineph­
rine. During the experiment, blood pressure and heart rate 
were monitored every 5 minutes by a Dinamap 1846 SX 
attached to the contralateral arm.
Direct Venous Vasoactivity of Furosemide
In a total of 20 subjects, NaCl 0.9% (0.1 mL/min) was 
replaced by five increasing doses of furosemide ( 1, 3, 10, 30,
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and 100 /xg/min) at the same infusion rate for 10 minutes each. 
The cuff was deflated for 30 seconds every 5 minutes. At the 
end o f the experiment, saline was infused again, still with 
concomitant norepinephrine infusion.
Involvement of Vascular Prostaglandin Synthesis in the 
Direct Venous Vasoactivity of Furosemide
In vivo, an increase in the venous capacitance induced by 
systemically administered furosemide has been reported to be 
inhibitable by indomethacin.3 This observation suggests a role 
for prostaglandins as a mediator of vasoactive effects of furo­
semide. The source of the prostaglandins involved in this 
mechanism may be the kidneys, because they may release 
prostaglandins into the systemic circulation3; alternatively, 
local production in the peripheral vasculature could be in­
volved J K To determine the role of the nonrenal prostaglandins 
in the venous vasoactive effects of furosemide, we examined the 
effect of locally administered indomethacin (12.5 jag/min, 10 
minutes) on the furosemide-induced venous vasoactivity. In 8 
subjects, furosemide (100 ¿¿g/min) together with a placebo 
(NaCl 0.9%, 0.1 mL/min) was locally infused into a precon­
stricted vein for 10 minutes. Venodilation was assessed, after 
which placebo was replaced by indomethacin for 10 minutes 
and venodilation was assessed again.
T o exclude a possible constrictor response by indomethacin 
alone, control experiments were performed in 4 subjects to 
determine the effect of indomethacin (12.5 and 125 /xg/min) on 
baseline venous tone.
Involvement of Vascular NO Synthesis in the Direct 
Venous Vasoactivity of Furosemide
N O  is a potent vasodilator released by vascular endothelial 
cells. Although the furosemide-induced vascular effects in vitro 
appear to be independent of the endothelium,7 a recent study 
showed that furosemide augmented the NO production of 
isolated cultured endothelial cells,1* To study the role of NO in 
the furosemide-induced venous vasoactivity, we repeated the 
protocol as described above, now using L-NMMA (60 pig/mi a) 
instead of indomethacin to inhibit NO production. Extensive 
studies have shown that this dose of L-NMMA has no effect on 
basal venous toneiy and is able to block the venodilation caused 
by acetylcholine.2“
Effect of Systemic Administration of Furosemide on 
D orsal Hand Vein Distensibility
All previous reports concerning the effects of furosemide on 
human vein capacitance used systemic administration. 10 To 
examine whether furosemide administered systemically in ther­
apeutic dosages exerts a vasodilator activity comparable to that 
o f locally administered furosemide, we administered furo­
sem ide (40 mg) intravenously in the contralateral arm in 15 
subjects. Venous distensibility of the precontracted hand vein 
was recorded during the following 8 minutes.
Drugs
Furosemide solutions were freshly prepared from 2-mL 
ampoules containing 10 mg/mL furosemide as a disodium salt 
(Lasix, Hoechst Marion Roussel) and were further diluted in 
physiological saline immediately before each experiment. Nor­
epinephrine (1-mg/mL ampoules), indomethacin (Indocid 
FD A , Merck Sharp and Dohme, 1 mg/mL), and L-NMMA 
acetate (Clinalfa) were dissolved in physiological saline imme­
diately before use.
D ata  Analysis
Data are expressed as mean±SEM unless noted otherwise 
and were analyzed by Student’s t test or repeated measures 
ANOVA for paired data if appropriate. If ANOVA showed 
that a significant difference existed between conditions, it was 
followed by post hoc / tests (including Bonferroni correction)
to determine dose dependency or time dependency. Linear 
regression analysis was performed on the relation between age 
and percentage furosemide-induced venodilation (correlation 
coefficient according to Pearson). A value of P<.05 was 
considered to indicate significance.
Direct arterial vasoactivity. To reduce the variability of blood 
flow data and to correct for systemic changes, the ratio of the 
FBF measurements in the infused and noninfused arms was 
calculated for each time point, with the noninfused arm used as 
a contemporaneous control for the infused arm.21 The FBF 
values of the last 3 minutes of each drug infusion were averaged 
to one value.
Direct venous vasoactivity. The response of norepinephrine- 
induced constriction was measured, and furosemide-induced 
effects were expressed as the percentage attenuation of the 
average control constriction. All results are expressed as a 
percentage of baseline vein size. The furosemide-induced 




Forearm volume averaged 984±32 mL. During the 
arterial vasoactivity experiments, blood pressure, heart 
rate, and FBF in the noninfused arm did not change 
significantly after intrabrachial infusion of furosemide. 
During local administration of furosemide in the venous 
vasoactivity experiments, blood pressure increased over 
««I hour from 113±2/62±1 to 116±2/66±2 mm Hg (for 
systolic and diastolic blood pressures, P=,03 and 
P -.0 0 1 , respectively, A N O V A  with repeated measures). 
There was no change in heart rate (61 ± 2  to 61 ±2  bpm, 
P =N S).
More relevantly, blood pressure increased within 5 
minutes after systemic administration of 40 mg of furo­
semide from 118±  1/68± 2  to 121±2/71±2 mm Hg 
(P=.01 and P c ,0001, respectively, Student’s t test). 
Heart rate remained unchanged (63±2 to 65±1 bpm).
Direct Effects on FBF
Ratios o f infused to control FBF and ipsilateral 
venous plasma concentrations of furosemide are shown 
in Fig 1 (top). During five increasing dosages of furo­
semide, there was no significant effect on FBF compared 
with the placebo infusion. In 6 subjects, we infused 
furosemide 1000 \xg * min“ 1 * dL“1 for 6 minutes, leading 
to local furosemide plasma concentrations of 234±40 
/xg/mL. In these subjects, furosemide increased FBF in 
the infused arm slightly, by 23±9.7% (P<.05), but 
without a significant effect on the FBF ratio of the 
infused and noninfused arms (P=.08).
Intra-arterial bum etanide infusions led to local 
plasma concentrations ranging from 39±11 to 1748±327 
ng/mL and also failed to alter FBF (data not shown).
Effect of furosemide on norepinephrine-induced vasocon­
striction. A s shown in Fig 1 (bottom), local infusion of 
norepinephrine into the brachial artery led to a dose- 
dependent decrease in FBF (7J<.001), with no significant 
effect on systemic blood pressure. This vasoconstriction 
was not inhibited by local infusion of furosemide
(P=N S).
Direct Effects on Dorsal Hand Vein Distensibility
Vein diameter of the participants was 0.74±0.05 mm. 
On average, infusion o f norepinephrine constricted the 
vein o f investigation to 31 ±2%  of the control size.
1850 Circulation Vol 96, No 6 September 16, 1997







% v e n o d i la t io n % v en o d ila t io n
^  V 
>' •' • .
• *• 
> . >tr , • x /f







0 1 3 10 3 0  100 0  1000
Furosem ide d o se  (yug/min/dl)
o  10 30  100
N orepinephrine dose (ng /m in /d l)
Fig 1, Direct arterial vasoactivity of furosemide. Top, Bars 
represent mean±SEM measured local venous plasma concen­
trations of furosemide (right axis). Line graph shows mean±SEM 
FBF ratio (infused/noninfused arm) during intrabrachial infusions 
of furosemide (left axis) as measured by venous occlusion 
plethysmography. There was no significant change in FBF ratio. 
Values are mean±SEM of 8 and 6 experiments. Bottom, Ratio of 
FBF during intrabrachial norepinephrine administration, both in 
the presence of placebo (solid circles/solid line) and after and 
during concomitant infusion of furosemide (10 /xg - min"1 * d L '1, 
open circles/dashed line). Constrictor response to norepineph­
rine (P<.001) was not inhibited by local furosemide administra­
tion (P=NS). Values are mean±S EM of 4 experiments. P values 
refer to statistical differences between conditions for these dose 
responses as analyzed by ANOVA with repeated measures over 
complete dose-response curves.
Fig 2 demonstrates that continuous local infusion of 
furosemide results in a dose-dependent attenuation of 
the constrictor effect of norepinephrine (P c.001). Post 
hoc t  tests (with Bonferroni correction) revealed a 
dose-dependent venodilation between doses of 0, 1 , 10, 
and 100 ¿ig/min. This direct venodilating effect of furo­
semide was rapid in onset. After the last furosemide 
infusion was replaced with NaCl 0.9% infusion, venodi­
lation waned within a few minutes.
Involvement of vascular prostaglandin synthesis in the direct 
venous vasoactivity of Jurosemide. In 8 subjects, furosemide- 
induced venorelaxation was assessed in the absence and 
presence of local indomethacin administration. Fig 3 (left) 
shows that indomethacin inhibits furosemide-induced 
venodilation, because in this subgroup, furosemide dilated 
the vein by 54±  17% and furosemide in combination with 
indomethacin, by 14±17%  (P=.025),
Control experiments showed that indomethacin itself 
had no constrictor effect on basal vein tone. When baseline 
vein distensibility is taken as 100%, indomethacin 12.5 and 
125 jLig/min led to vein distensibilities of 101.4±0.5% and 
100.2±1.2%, respectively (n=4, P=N S),
Involvement of vascular NO synthesis in the direct venous 
vasoactivity of furosemide. Fig 3 (right) shows that furo­
semide-induced venorelaxation was not inhibited by 
local L-NM M A administration. In this subgroup, veno­
relaxation was 60±11%  before and 53±14%  after pla­
cebo was replaced by L-NM M A (n = 8, P = N S ).
Effect o f systemic administration of furosemide on dorsal 























Furosemide dose (¿¿g/min) Time (min)
F ig 2. Direct venous vasoactivity of furosemide. Left, Percent­
age increase in venous distensibility of a norepinephrine-con­
stricted dorsal hand vein before and during increasing doses of 
local furosemide infusions. Values are mean±SEM of 20 exper­
iments. Horizontal axis indicates dose infused per minute, not 
final concentration. Right, Percentage increase in venous dis­
tensibility of a norepinephrine-constricted dorsai hand vein after 
contralateral systemic administration of furosemide (40 mg) at 2, 
4, and 8 minutes after bolus injection. Values are mean±SEM of 
15 experiments. P values refer to statistical differences between 
conditions for these dose- or time-dependent responses as 
analyzed by ANOVA with repeated measures over complete 
dose-response curves.
teral administration (contralateral antecubital vein) of 
40 mg furosemide led to increases in vein diameter of 
1S±8%, 26±11% , and 45±11%  at 2, 4, and 8 minutes, 
respectively (P<.01). Post hoc tests (Bonferroni) re­
vealed that venodilation was significantly different from 
baseline at t= 4  minutes (P=.028) and 8 minutes 
(P=.Q01).
Discussion
It is generally accepted that the reduction in venous 
return as a result of a nondiuretic vascular effect by 
furosemide is therapeutically important in achieving 
rapid symptomatic relief for patients with left ventricular 
heart failure. The mechanism of this action is unclear. 
Because of the absence of data on the direct vasoactivity 
o f furosemide in vivo, we examined the vascular effects 
of local furosemide administration on arterial and ve­
nous vessels in humans. Our data strongly suggest that 
furosemide does not exert any direct arterial vasodilator 










Placebo Indomethacin Placebo L-NM M A
F ig 3. Percentage increase in venous distensibility of a norepi­
nephrine-constricted dorsal hand vein induced by local admin­
istration of furosemide (100 /j,g/min) both in the presence of 
placebo and after and during concomitant infusion of indometh- 
acin (12.5 ¿¿g/min, left; P<.025) or L-NMMA (60 jug/min, right; 
P=NS). Values are mean±SEM of 8+8 experiments. P values 
refer to statistical differences between conditions as analyzed by 
Student’s t  test for paired data.
Pickkers et al Direct Vasoactivity of Furosemide in Huinans 1851
does have a direct venodiiator effect, which is associated 
with vascular prostaglandin synthesis.
Direct Effects on FBF
Our results demonstrate the absence of a direct effect 
of loop-active diuretics on FBF during intra-arterial 
infusions, which results in clinically relevant plasma 
concentrations in the infused forearm. The absence of 
vasoactivity in this concentration range is consistent with 
most previous experiments on isolated arteries.7’9 In 
these in vitro experiments, direct vasodilator properties 
of furosemide were observed only at concentrations 
>10"4 mol/L, whereas in our first series of experiments, 
the furosemide concentration at the highest infusion 
rate reached 47±10 ¿¿g/mL, equivalent to 1.4X 10'4 
mol/L. To examine the direct arterial effects of furo­
semide at very high concentrations in vivo, we infused 
furosemide 1000 ¡xg * min"1 * dL“1 into the brachial 
artery, leading to a local concentration of 234±40  
¿¿g/mL (0.71 X10"3 mol/L). Even at these suprathera- 
peutic concentrations, only a negligible increase in FBF 
was observed.
In the rat, furosemide did not change baseline mes­
enteric blood flow, but systemic administration did in­
hibit the decrease in blood flow produced by angiotensin
II and norepinephrine.14 In contrast, we observed no 
effect of local furosemide on norepinephrine-induced 
attenuation of FBF. From our studies, we conclude that 
furosemide does not exert any direct arterial vasodilator 
or antivasoconstrictor activity in the human forearm. As 
such, the previously reported decrease in FBF after 
systemic administration of furosemide3-4’22 is probably 
due to an indirect effect of the drug, in particular a 
stimulation of the renin-angiotensin system.5 O f course, 
our experiments do not allow us to exclude direct 
arterial vasoactivity of furosemide in other vascular 
beds, eg, the lung or kidney.
Direct Effects on Dorsal Hand Vein Distensibility
The present investigation shows that furosemide exerts a 
direct vasodilator effect on preconstricted dorsal hand 
veins. Time-controi experiments demonstrated that this 
effect of furosemide cannot be explained by a spontaneous 
reduction in norepinephrine-induced constriction over 
time. The local concentration of furosemide cannot be 
estimated precisely because the venous flow was not mea­
sured in these studies. However, if the flow in the dorsal 
hand vein is assumed to be 1 mL/min (5%  of arterial 
F),23 furosemide plasma concentrations can be esti­
mated to range from 0.2 to 20 jug/mL during our dose- 
response studies. Systemic administration of 40 mg furo­
semide leads to a plasma concentration of 3.8 ±0.3 jitg/mL 
in the first 15 minutes in normal subjects,24 which is within 
the range of the estimated plasma concentrations. This, as 
well as the observation of a similar venodiiator effect after 
systemic administration of 40 mg furosemide, suggests that 
the increase of venous compliance observed after systemic 
administration of furosemide may be the result of direct 
effects on the venous circulation. Compared with other 
substances such as nitroprusside25 and substance P,26 which 
exert venodilatory properties at an infusion rate of nano­
grams per minute, furosemide is much less potent. How­
ever, its effect does have clinical relevance, especially in the 
first few minutes after parenteral administration.
Mechanism of Action
Two hypotheses concerning the direct vascular effects 
of furosemide emerge from the literature. The first 
hypothesis focuses on furosemide-induced inhibition of 
vascular Na-K -2 Cl cotransport, whereas the second is 
directed to the role of prostaglandins in the vascular 
activity of furosemide.
N a-K -2 Cl Cotransport Inhibition
The presence of Na-K -2 Cl cotransport in endothelial 
and vascular smooth muscle cells has been established, 
but its role in the regulation of vascular tone is un­
clear.27-29 In a recent report, furosemide relaxed canine 
venous but not arterial vessels taken from a variety of 
vascular beds,9 In the same vessels, N a-K -2 Cl cotrans­
port distribution was determined, and the magnitude of 
the vasodilator effect was found to correlate with Na- 
K -2 Cl cotransport distribution. The correlation be­
tween Na-K-2 Cl cotransport distribution and vascular 
activity suggests a role for this cotransporter in the 
vascular action of furosemide. However, inhibition of 
renal Na-K-2 Cl cotransport occurs at 10“4 to 10~3 
mol/L furosemide,30 concentrations 10 to 50 times the 
local concentration in the hand vein, and the importance 
of this action of furosemide to its venodiiator properties 
remains uncertain,
Augmented Prostaglandin Synthesis
The effect of systemic administration o f furosemide 
on venous capacitance has been compared between 
healthy subjects and anephric patients. V enous capaci­
tance increased in healthy volunteers but not in anephric 
patients,3 This effect could be blocked by pretreatment 
of the cyclooxygenase inhibitor indomethacin, suggest­
ing a role for renal prostaglandin release in the vascular 
effects of furosemide. Our results indicate that renal 
prostaglandin synthesis is not necessarily important for 
the direct venous vasodilation, because the release of 
renal prostaglandins cannot have been stimulated after 
the local furosemide infusions. This does not rule out 
the possibility that furosemide-induced vasodilation 
is mediated by activation of vascular PG I2 synthesis. 
Lundergan et al,31 using an isolated canine lung lobe 
perfused with autologous blood at constant flow, dem­
onstrated that furosemide-induced decreases in pulmo­
nary artery perfusion pressure were mediated by pros­
taglandins because they were abolished by treatment of 
the lung with indomethacin. Recently, it was shown in 
cultured bovine aortic endothelial cells that furosemide 
stimulated the production of prostacyclin and NO at 
clinically relevant concentrations.IR In our study, the 
direct venodiiator effect of furosemide on veins was 
almost totally abolished by local administration o f indo­
methacin, indicating that this direct vascular effect is 
dependent on local vascular prostaglandin synthesis. It is 
unclear whether the endothelial or the vascular smooth 
muscle cell is the source of the prostaglandin production 
augmented by furosemide. In vivo endothelial stripping 
with distilled water32 seems a possibility to address this 
question, but these experiments are quite invasive, and 
NSAID treatment will be necessary to prevent blood 
clotting,32 which will obscure the interpretation of the 
furosemide-induced venodilation. It is unknown whether 
the furosemide-enhanced vascular PGI2 production18 is
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the consequence of a nonspecific action of furosemide or 
of inhibition of the vascular Na-K -2 Cl cotransporter. 
Furthermore, the effect of systemic treatment with indo­
methacin or other NSAIDs on the furosemide-induced 
venorelaxation and its clinical implications are unknown.
The venorelaxation persisted after addition of 
L-NMMA, so it appears that the effect is not mediated  
by endothelial NO release.
Conclusions
The present study provides the first evidence that 
furosemide at therapeutic concentrations exerts no di­
rect vasodilator or antivasoconstrictor effect on arterial 
resistance vessels in the human forearm but rather 
directly dilates veins in humans. The direct venodilation 
was inhibited by local indomethacin administration but 
not by blockade of NO synthesis, indicating that the 
direct vascular venodilation is dependent on local pros­
taglandin but not on NO production. Hemodynamic 
changes observed directly after systemic administration 
of furosemide are probably due to a direct venodiiator 
effect of the drug.
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